Neurology
-
Randomized Controlled Trial
Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial.
To assess efficacy and safety of fulranumab, a fully human monoclonal antibody against nerve growth factor, in patients with diabetic peripheral neuropathic pain (DPNP). ⋯ This study provides Class I evidence that in patients with DPNP, fulranumab 10 mg reduces pain by 1.2 points on an 11-point scale compared with placebo.